Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2022, Turning Point Therapeutics, Inc. (the "Company") held its 2022 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 18, 2022, the record date for the Annual Meeting, 49,666,288 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest round number.

Proposal 1: Election of Directors

The Company's stockholders elected the two persons listed below as Class III directors, each to serve until the Company's 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

Name of Director Elected Votes For Votes Withheld Broker Non-Votes

Mark J. Alles 31,342,218 13,093,788 2,099,409

Barbara W. Bodem 30,460,874 13,975,132 2,099,409

Proposal 2: Advisory Vote on Executive Compensation

The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the proxy statement. The final voting results are as follows:

Votes For Votes Against Abstentions Broker Non-Votes 29,055,338 13,851,055 1,529,613 2,099,409

Proposal 3: Ratification of the Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:

Votes For Votes Against Abstentions Broker Non-Votes 46,459,043 64,181 12,191

             -

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses